EXTON, PA — West Pharmaceutical Services Inc. (NYSE: WST) has opened a 165,000-square-foot expansion at its Damastown site in Dublin to increase contract manufacturing capacity for high-volume injectable therapies, including treatments for diabetes and obesity.
The new facility expands the company’s ability to support drug handling at commercial scale as demand grows for complex injectable delivery systems.
The expansion adds capabilities beyond component molding, device assembly, and packaging to include advanced automation and expanded drug-handling operations.
Aileen Ruff-Patry, president of contract manufacturing at West, said the site will support production of next-generation therapies. “This expansion increases our global capacity to support drug handling for high-volume injectable therapies, including next-generation GLP-1 treatments,” she said.
The Damastown facility is part of West Vantage, the company’s contract services business, which provides development, manufacturing, packaging, testing, and regulatory support.
West Pharmaceutical Services, based in Exton, Pennsylvania, employs more than 10,000 people across 50 sites worldwide and reported $3.07 billion in net sales in fiscal year 2025.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.